Aclaris Therapeutics, Inc. Defined Contribution Plan, Cost
Aclaris Therapeutics, Inc. (ACRS) reported Defined Contribution Plan, Cost of $400.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2025-02-27
- Aclaris Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $400.00K, a 42.86% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $700.00K, a 40.00% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. defined contribution plan, cost for fiscal 2022 was $500.00K, a 66.67% increase from fiscal 2021.
- Aclaris Therapeutics, Inc. defined contribution plan, cost for fiscal 2021 was $300.00K, a 25.00% decline from fiscal 2020.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2024-12-31 | $400.00K 10-K · filed 2025-02-27 | |
| 2023-12-31 | $700.00K 10-K · filed 2025-02-27 | |
| 2022-12-31 | $500.00K 10-K · filed 2024-02-27 | |
| 2021-12-31 | $300.00K 10-K · filed 2024-02-27 | |
| 2020-12-31 | $400.00K 10-K · filed 2023-02-23 | |
| 2019-12-31 | $700.00K 10-K · filed 2022-02-24 | $740.00K 10-K · filed 2020-02-25 |
| 2018-12-31 | $700.00K 10-K · filed 2021-02-25 | $662.00K 10-K · filed 2019-03-18 |
| 2017-12-31 | $270.00K 10-K · filed 2020-02-25 | |
| 2016-12-31 | $176.00K 10-K · filed 2019-03-18 | |
| 2015-12-31 | $99.00K 10-K · filed 2018-03-12 | |
| 2014-12-31 | $60.00K 10-K · filed 2017-03-15 | |
| 2013-12-31 | $51.00K 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |